Use to monitor subclinical paroxysmal nocturnal hemoglobinuria and eculizumab treatment. Preferred initial diagnostic test is Paroxysmal Nocturnal Hemoglobinuria (PNH), RBC and WBC (2005006).
- Patient Preparation
- New York State Clients: Testing is only approved for the Paroxysmal Nocturnal Hemoglobinuria (PNH), High Sensitivity, RBC and WBC (ARUP test code 2005006) on whole blood specimens.
- Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
- Specimen Preparation
- Transport 4 mL whole blood. (Min: 0.5 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Bone marrow. Clotted or hemolyzed specimens.
- Specimens must be analyzed within stability times provided.
- Ambient: 4 days; Refrigerated: 4 days; Frozen: Unacceptable
The lower limit of detection of this test is 0.005 percent PNH cells. This test will distinguish between Type II and Type III cells when the PNH cell percentage is 1.000 or greater. Glycophorin A (CD235a) is used to gate the RBC population. CD59 is the GPI-linked antigen. Recent RBC transfusions may decrease the percentage of PNH cells measured in RBCs (Cytometry 2000; 42:223-33).
For the most accurate measurement of the PNH clone size, order Paroxysmal Nocturnal Hemoglobinuria, High Sensitivity, WBC (ARUP test code 2005003) to assist with therapeutic decisions in conventional PNH.
For initial diagnosis of PNH and analysis of both RBCs and WBCs, order Paroxysmal Nocturnal Hemoglobinuria (PNH), High Sensitivity, RBC and WBC (ARUP test code 2005006).
|Component Test Code*||Component Chart Name||LOINC|
|2004367||% PNH RBC||33662-8|
- 59 and Glycophorin A
- PI-Linked Antigens on RBCs